Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P120016/S039

VASCADE MVP XL VVCS Model 800-1014XL

Cardiva Medical, Inc. · Decision date Mar 27, 2026

FDA DECISIONP120016/S039

What did the FDA approve?

FDA records P120016/S039 as a supplement to PMA P120016, with the supplement type “Panel Track”. The recorded decision is approval, dated Mar 27, 2026.

FDA approval order statement

The VASCADE MVP XL Venous Vascular Closure System (VVCS) Model 800-1014XL is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 8 14F inner diameter (17F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs. The VASCADE MVP XL Venous Vascular Closure System (VVCS) Model 800-1014XL is also indicated for enabling same day discharge in patients who have undergone catheter-based cardiac arrhythmia ablation procedures utilizing 8 14F inner diameter (17F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Cardiovascular
Decision date
Mar 27, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P120016/S039
Regulatory pathway
PMA supplement
Product code
MGB
Decision code
APPR
Decision date
Mar 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, hemostasis, vascular.

Product code
MGB
FDA device class
3

For the original device and its historical approval scope, see PMA P120016. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P120016 · Original PMA

    VASCADE VASCULAR CLOSURE SYSTEM

  2. P120016/S039 received

    Application receipt date recorded by FDA.

  3. P120016/S039 · FDA decision

    Panel Track

  4. P120016/S040 · Related supplement

    Cardiva, VASCADE Family

  5. P120016/S043 · Related supplement

    VASCADE 5F Vascular Closure System

Timeline entries are records held by MedtechLedger for P120016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P120016

Product / regulatory recordCompanyPathwayDecision dateSource
Cardiva Medical, Inc.PMA approvalJan 31, 2013FDA
Cardiva Medical, Inc.PMA supplementApr 23, 2026FDA
Cardiva Medical, Inc.PMA supplementSep 10, 2026FDA

Explore the linked device profile

Other records with product code MGB

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cardiva Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2900 Lakeside Dr., Suite 160, Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records